Argo assisted longstanding client Vendis and management on the sale of Sylphar International NV to Karo Pharma
Argo advised longstanding client Vendis and management (including, CEO Robin List) on the sale of Sylphar International NV to Karo Pharma, a Swedish healthcare company listed on Nasdaq Stockholm for EUR 290mio (excluding, potential earn-outs). Karo Pharma is backed by its majority shareholder, leading European private equity fund EQT.
Sylphar is headquartered in Deurle, Belgium and employs around 70 people in Belgium and the UK. It develops and markets over-the-counter products such as Nutravita, IWhite, Alpha Foods and Remescar, worldwide through a digital-first strategy. Argo also advised on the subsequent reinvestment by Management.